Clinical Trial Update: Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure [Phase 3]

View source ↗

Summary

Phase 3 trial assessing ampRELOXetine (TD-9855) for symptomatic neurogenic orthostatic hypotension due to primary autonomic failure has completed, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autonomic Failure
• Neurogenic Orthostatic Hypotension

Drugs mentioned

• Ampreloxetine (TD-9855) (ampelexotide? (Note: Ampreloxetine is the correct generic name; TD-9855 is the investigational code))

Snippet

Sponsor: Theravance Biopharma | Conditions: Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Status: COMPLETED | Results posted: 2022-09-14